Ameritas Investment Partners’s Black Diamond Therapeutics BDTX Stock Holding History

Ameritas Investment Partners’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3,639	Closed	-$5.64K	–	3214
2025 Q1	$5.64K	Hold	3,639	–	–	﹤0.01%	2948
2024 Q4	$7.79K	Hold	3,639	–	–	﹤0.01%	2965
2024 Q3	$15.8K	Hold	3,639	–	–	﹤0.01%	2752
2024 Q2	$17K	Buy	+3,639	New	+$19.5K	﹤0.01%	2682
2022 Q2	–	Sell	-1,541	Closed	-$4K	–	3079
2022 Q1	$4K	Hold	1,541	–	–	﹤0.01%	2987
2021 Q4	$8K	Hold	1,541	–	–	﹤0.01%	2949
2021 Q3	$13K	Hold	1,541	–	–	﹤0.01%	2862
2021 Q2	$19K	Hold	1,541	–	–	﹤0.01%	2754
2021 Q1	$37K	Hold	1,541	–	–	﹤0.01%	2252
2020 Q4	$49K	Hold	1,541	–	–	﹤0.01%	2002
2020 Q3	$47K	Buy	1,541 +491	+47%	+$14.9K	﹤0.01%	1869
2020 Q2	$44K	Hold	1,050	–	–	﹤0.01%	1905
2020 Q1	$26K	Buy	+1,050	New	+$32K	﹤0.01%	2026

Other funds holding BDTX

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Ameritas Investment Partners's BDTX Position: Q2 2025 in Review

Ameritas Investment Partners sold out of Black Diamond Therapeutics (BDTX) in Q2 2025, closing a stake of 3,639 shares — an estimated $5.64K sold.

Ameritas Investment Partners first reported a position in BDTX in Q1 2020 and held it in 13 quarters. The position peaked at $49K in Q4 2020. 94 funds tracked by Wall St. Rank hold BDTX as of Q2 2025.

Ameritas Investment Partners reported no remaining Black Diamond Therapeutics position as of Q2 2025 after selling out during the quarter.
Ameritas Investment Partners sold 3,639 Black Diamond Therapeutics shares in Q2 2025, an estimated $5.64K.
Ameritas Investment Partners first reported a position in Black Diamond Therapeutics in Q1 2020 and held it in 13 quarters.
Ameritas Investment Partners's Black Diamond Therapeutics position peaked at $49K in Q4 2020.
94 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2025.

Based on Ameritas Investment Partners's 13F filing for Q2 2025, filed 12 Aug 2025.